NICE hears Bayer's Nexavar appeal
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, on Friday heard Bayer's appeal against the institute's guidance that rejected Nexavar (sorafenib) for advanced hepatocellular carcinoma for use on the NHS.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.